Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection

Olav Dalgard, Alessandra Mangia

Research output: Contribution to journalArticlepeer-review

Abstract

In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations

Original languageEnglish
Pages (from-to)1807-1815
Number of pages9
JournalDrugs
Volume66
Issue number14
DOIs
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection'. Together they form a unique fingerprint.

Cite this